Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?
Article first published online: 3 DEC 2012
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology
Clinical & Experimental Immunology
Volume 171, Issue 1, pages 8–19, January 2013
How to Cite
Simoni, Y., Diana, J., Ghazarian, L., Beaudoin, L. and Lehuen, A. (2013), Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?. Clinical & Experimental Immunology, 171: 8–19. doi: 10.1111/j.1365-2249.2012.04625.x
- Issue published online: 3 DEC 2012
- Article first published online: 3 DEC 2012
- Accepted manuscript online: 22 JUN 2012 08:55AM EST
- Accepted for publication 1 June 2012
- NK T cells;
T cells reactive to lipids and restricted by major histocompatibility complex (MHC) class I-like molecules represent more than 15% of all lymphocytes in human blood. This heterogeneous population of innate cells includes the invariant natural killer T cells (iNK T), type II NK T cells, CD1a,b,c-restricted T cells and mucosal-associated invariant T (MAIT) cells. These populations are implicated in cancer, infection and autoimmunity. In this review, we focus on the role of these cells in autoimmunity. We summarize data obtained in humans and preclinical models of autoimmune diseases such as primary biliary cirrhosis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis and atherosclerosis. We also discuss the promise of NK T cell manipulations: restoration of function, specific activation, depletion and the relevance of these treatments to human autoimmune diseases.